Is sofosbuvir/ledipasvir safe for the hearts of children with hepatitis C virus?

Medhat, 2002, Hepatitis C in a community in Upper Egypt: risk factors for infection, Am J Trop Med Hyg, 66, 633, 10.4269/ajtmh.2002.66.633 Habib, 2001, Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity, Hepatology, 33, 248, 10.1053/jhep.2001.20797 Kamal, 2011, Hepatitis C virus genotype 4 therapy: progress and challenges, Liver Int, 31, 45, 10.1111/j.1478-3231.2010.02385.x Kamal, 2008, Hepatitis C genotype 4: what we know and what we don’t yet know, Hepatology, 47, 1371, 10.1002/hep.22127 Reddy, 2009, Ribavirin: current role in the optimal clinical management of chronic hepatitis C, J Hepatol, 50, 402, 10.1016/j.jhep.2008.11.006 Ghany, 2009, Diagnosis, management and treatment of hepatitis C: an update, Hepatology, 49, 1335, 10.1002/hep.22759 Kamal, 2014, Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents, Hepat Med, 6, 61, 10.2147/HMER.S41127 El-Karaksy, 2016, Safety and efficacy of combined treatment with pegylated interferon alpha-2b and ribavirin for HCV genotype 4 in children, J Interferon Cytokine Res, 36, 1, 10.1089/jir.2015.0066 European Association for Study of Liver, 2015, EASL recommendations on treatment of hepatitis C 2015, J Hepatol, 63, 199, 10.1016/j.jhep.2015.03.025 Sulkowski, 2014, Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, N Engl J Med, 370, 211, 10.1056/NEJMoa1306218 Lawitz, 2014, Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial, Lancet, 383, 515, 10.1016/S0140-6736(13)62121-2 Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454 Food and Drug Administration FDA drug safety communication. FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral drug, http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm. [Accessed 15 September 2016]. Fontaine, 2015, Bradyarrhythmias associated with sofosbuvir treatment, N Engl J Med, 373, 1886, 10.1056/NEJMc1505967 Kuo, 1983, Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations, Circulation, 67, 1356, 10.1161/01.CIR.67.6.1356 Kors, 2008, The meaning of the Tp-Te interval and its diagnostic value, J Electrocardiol, 41, 575, 10.1016/j.jelectrocard.2008.07.030 Castro Hevia, 2006, Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome, J Am Coll Cardiol, 47, 1828, 10.1016/j.jacc.2005.12.049 Smetana, 2011, Assessment of repolarization heterogeneity for prediction of mortality in cardiovascular disease: peak to the end of the T wave interval and nondipolar repolarization components, J Electrocardiol, 44, 301, 10.1016/j.jelectrocard.2011.03.004 Bazett, 1920, An analysis of the time-relations of electrocardiograms, Heart, 7, 353 Durante-Mangoni, 2017, Electrophysiological adverse effects of direct acting antivirals in patients with chronic hepatitis C, J Clin Pharmacol, 57, 924, 10.1002/jcph.872 Matsumori, 1998, Hepatitis C virus infection and heart diseases: a multicenter study in Japan, Jpn Circ J, 62, 389, 10.1253/jcj.62.389 Bernardi, 1998, Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors, Hepatology, 27, 28, 10.1002/hep.510270106 Gassanov, 2014, Cirrhotic cardiomyopathy: a cardiologist’s perspective, World J Gastroenterol, 20, 15492, 10.3748/wjg.v20.i42.15492 Zambruni, 2007, QT interval correction in patients with cirrhosis, J Cardiovasc Electrophysiol, 18, 77, 10.1111/j.1540-8167.2006.00622.x Mozos, 2011, Factors associated with a prolonged QT interval in liver cirrhosis patients, J Electrocardiol, 44, 105, 10.1016/j.jelectrocard.2010.10.034 Lanzieri, 2017, Cirrhotic patients with Child-Pugh C have longer QT intervals, Int J Cardiovasc Sci, 30, 496 Zamirian, 2012, Corrected QT interval and QT dispersion in cirrhotic patients before and after liver transplantation, Arch Iran Med, 15, 375 Rumbo, 2006, Hepatitis C in children: a quaternary referral center perspective, J Pediatr Gastroenterol Nutr, 43, 209, 10.1097/01.mpg.0000228117.52229.32 Goodman, 2008, Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial, Hepatology, 47, 836, 10.1002/hep.22094 Gilead Sciences, 2015